Messig M - Search Results

1

Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).

Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Rossignol P, et al. Among authors: messig m. Circ Heart Fail. 2014 Jan;7(1):51-8. doi: 10.1161/CIRCHEARTFAILURE.113.000792. Epub 2013 Dec 2. Circ Heart Fail. 2014. PMID: 24297687 Clinical Trial.

2

Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).

Shepherd J, Breazna A, Deedwania PC, LaRosa JC, Wenger NK, Messig M, Wilson DJ; Treating to New Targets Steering Committee and Investigators. Shepherd J, et al. Among authors: messig m. Am J Cardiol. 2016 Apr 15;117(8):1199-205. doi: 10.1016/j.amjcard.2016.01.014. Epub 2016 Jan 28. Am J Cardiol. 2016. PMID: 26940556 Free article.

3

Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Amarenco P, Goldstein LB, Messig M, O'Neill BJ, Callahan A 3rd, Sillesen H, Hennerici MG, Zivin JA, Welch KM; SPARCL Investigators. Amarenco P, et al. Among authors: messig m. Stroke. 2009 Jul;40(7):2486-92. doi: 10.1161/STROKEAHA.108.546135. Epub 2009 May 21. Stroke. 2009. PMID: 19461031 Clinical Trial.

4

Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.

Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, Breazna A, Pedersen TR. Waters DD, et al. Among authors: messig m. J Am Coll Cardiol. 2013 Jan 15;61(2):148-52. doi: 10.1016/j.jacc.2012.09.042. Epub 2012 Dec 5. J Am Coll Cardiol. 2013. PMID: 23219296 Free article. Clinical Trial.

5

Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease.

Bittner V, Wenger NK, Waters DD, DeMicco DA, Messig M, LaRosa JC. Bittner V, et al. Among authors: messig m. Am Heart J. 2012 Sep;164(3):387-93. doi: 10.1016/j.ahj.2012.06.016. Am Heart J. 2012. Retraction in: Am Heart J. 2013 Jul;166(1):197. doi: 10.1016/j.ahj.2013.06.001 PMID: 22980306 Retracted. Clinical Trial.

6

Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study).

Ong KL, Waters DD, Messig M, DeMicco DA, Rye KA, Barter PJ. Ong KL, et al. Among authors: messig m. Am J Cardiol. 2014 May 15;113(10):1593-8. doi: 10.1016/j.amjcard.2014.02.011. Epub 2014 Mar 1. Am J Cardiol. 2014. PMID: 24666618 Clinical Trial.

7

Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study).

Arsenault BJ, Kohli P, Lambert G, DeMicco DA, Laskey R, Messig MM, Kastelein JJ, Waters DD. Arsenault BJ, et al. Among authors: messig mm. Am J Cardiol. 2016 Aug 15;118(4):494-8. doi: 10.1016/j.amjcard.2016.05.044. Epub 2016 May 29. Am J Cardiol. 2016. PMID: 27328952

8

Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies.

Gandelman K, Fung GL, Messig M, Laskey R. Gandelman K, et al. Among authors: messig m. Am J Ther. 2012 May;19(3):164-73. doi: 10.1097/MJT.0b013e3181f28fb5. Am J Ther. 2012. PMID: 20975528

9

Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.

Amarenco P, Callahan A 3rd, Campese VM, Goldstein LB, Hennerici MG, Messig M, Sillesen H, Welch KM, Wilson DJ, Zivin JA. Amarenco P, et al. Among authors: messig m. Stroke. 2014 Oct;45(10):2974-82. doi: 10.1161/STROKEAHA.114.005832. Epub 2014 Aug 21. Stroke. 2014. PMID: 25147328 Clinical Trial.

10

Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL.

Kohli P, Waters DD, Nemr R, Arsenault BJ, Messig M, DeMicco DA, Laskey R, Kastelein JJP. Kohli P, et al. Among authors: messig m. J Am Coll Cardiol. 2015 Feb 3;65(4):402-404. doi: 10.1016/j.jacc.2014.10.053. J Am Coll Cardiol. 2015. PMID: 25634843 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters